DRTG(SH:600329) Zheng Quan Zhi Xing·2025-03-30 08:21Core Points - The Supervisory Board of Tianjin Pharmaceutical Darentang Group Co., Ltd. held its first meeting of 2025 on March 28, 2025, with all three supervisors present, confirming compliance with company regulations [1] - The Supervisory Board approved the 2024 annual work report, annual financial report, and profit distribution plan, all receiving unanimous support [1][2][3] - The Supervisory Board expressed independent opinions on the company's operations, confirming adherence to legal and regulatory requirements, and the effectiveness of internal controls [2][3] Summary by Sections - Annual Work Report: The Supervisory Board reviewed and approved the 2024 annual work report with a unanimous vote [1] - Annual Financial Report: The financial report for 2024 was reviewed and deemed accurate, receiving unanimous approval [1][2] - Profit Distribution Plan: The profit distribution plan for 2024 was found to comply with relevant regulations and was approved for submission to the shareholders' meeting [2] - Supervisory Opinions: The Supervisory Board monitored the company's operations and confirmed that the Board of Directors operated within legal frameworks, protecting minority shareholders' rights [2][3] - Internal Control Evaluation: The internal control evaluation report for 2024 was reviewed and approved unanimously [3] - Use of Raised Funds: The report on the use of raised funds was reviewed and approved, confirming compliance with regulations [3] - Risk Assessment Report: The risk assessment report for Tianjin Pharmaceutical Group Financial Co., Ltd. was approved [3] - Investment Project Adjustments: The Board approved adjustments to investment projects and the use of surplus funds for working capital [3][4] - Supervisor Compensation: The total compensation for supervisors for 2024 was approved [4] - Asset Impairment Provisions: The provisions for asset impairment for 2024 were reviewed and approved [4]